애딕스 테라퓨틱스(ADR)(ADXN)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.40 (+1.19%), 시가총액 $8.75M.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder.
애딕스 테라퓨틱스(ADR)의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
애딕스 테라퓨틱스(ADR)의 현재 주가는 $3.40 (+1.19%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
애딕스 테라퓨틱스(ADR)의 시가총액은 약 $8.75M입니다.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.